Kathleen Moore
Nebraska Medical Center · The University of Oklahoma College of Medicine · University of South Florida
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kathleen Moore as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:53 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07737795 · Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial CancerUniversity of Oklahoma · not yet recruiting · Endometrial Cancer · principal investigator
- Ph1/Ph2NCT06545617 · A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian CancerBio-Thera Solutions · withdrawn · Platinum-resistant Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer · principal investigator
- N/ANCT05184907 · Effects of RME on Engagement in Buprenorphine TreatmentCambridge Health Alliance · completed · Opioid Use Disorder, Behavioral Symptoms, Psychiatric or Mood Diseases or Conditions · principal investigator
- N/ANCT04822168 · Effects of Remote Motivational Enhancement & MySafeRx on Post-Detox Engagement in B/N Treatment -RCTUniversity of South Florida · withdrawn · Opioid-use Disorder · principal investigator
- N/ANCT04449744 · Evaluating Adaptive Dispenser Initiation Protocols for MySafeRx During Post-detox Buprenorphine Treatment- a Pilot StudyUniversity of South Florida · completed · Opioid-use Disorder · principal investigator
- Ph2NCT03526432 · Phase II Study of Atezolizumab + Bevacizumab in Endometrial CancerUniversity of Oklahoma · active not recruiting · Endometrial Cancer · principal investigator
- Ph2NCT03476798 · Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or EndometriumUniversity of Oklahoma · completed · Cervical Cancer, Endometrial Cancer · principal investigator
- Ph1NCT03206177 · Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or OvaryUniversity of Oklahoma · completed · Carcinosarcoma, Ovarian · principal investigator
- Ph1NCT03206645 · Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant ChemotherapyUniversity of Oklahoma · completed · Ovarian Cancer · study chair
- Ph2NCT03189446 · Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial CancerUniversity of Oklahoma · completed · Endometrial Cancer, Papillary Serous, Clear Cell Endometrial Cancer · principal investigator
- Ph2NCT02272790 · Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerAstraZeneca · completed · Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation · principal investigator
- Ph3NCT01844986 · Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.AstraZeneca · active not recruiting · Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV · principal investigator
- Ph2NCT01210222 · Trebananib in Treating Patients With Persistent or Recurrent Endometrial CancerGynecologic Oncology Group · completed · Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma · principal investigator
- Ph1NCT00666991 · Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal CancersCritiTech, Inc. · completed · Peritoneal Neoplasms · principal investigator
- Ph1NCT00104910 · Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical CancerGynecologic Oncology Group · completed · Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Imaging and Data Resources CoreP20GM135009 · NIGMS · UNIVERSITY OF OKLAHOMA · fiscal years 2022 to 2026 · $246,764 awarded in 2026Same name and institution; not confirmed by an ID
- Leadership, Planning and EvaluationP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · fiscal years 2025 to 2026 · $116,659 awarded in 2026Same name and institution; not confirmed by an ID
- Oklahoma TRUST Access HubUG1CA287044 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · fiscal years 2024 to 2025 · $821,025 awarded in 2025Same name and institution; not confirmed by an ID
- Clinical Protocol and Data ManagementP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · fiscal years 2018 to 2024 · $206,791 awarded in 2024Same name and institution; not confirmed by an ID
- A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical TrialsUG1CA233193 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · fiscal years 2019 to 2023 · $1,871,024 awarded in 2023Same name and institution; not confirmed by an ID
- Summer Research Institute at the Florida Mental Health InstituteR25DA043224 · NIDA · UNIVERSITY OF SOUTH FLORIDA · fiscal years 2018 to 2023 · $104,788 awarded in 2023Same name and institution; not confirmed by an ID
- Targeting HPV Consequences in a Cervical Cancer Clinical TrialR01CA200126 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · fiscal years 2020 to 2021 · $204,490 awarded in 2021Same name and institution; not confirmed by an ID
- Effects of remote motivational enhancement and MySafeRX on post-detox engagement and retention in buprenorphine treatmentR01CE003039 · NCIPC · UNIVERSITY OF SOUTH FLORIDA · fiscal years 2018 to 2020 · $750,000 awarded in 2020Grant number is on one of their registry trials
- Lead Academic Participating Site for the Development and Conduct of NCTN TrialsU10CA180798 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · fiscal years 2017 to 2018 · $250,000 awarded in 2018Same name and institution; not confirmed by an ID
- IPV and Fatherhood Intervention in Residential Substance Abuse TreatmentR34DA038763 · NIDA · UNIVERSITY OF SOUTH FLORIDA · fiscal years 2017 · $224,250 awarded in 2017Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Route 66 Endometrial Cancer SPOREP50CA265793 · NCI · WASHINGTON UNIVERSITY · PI DORIS Mangiaracina BENBROOK, Kimberly K. Leslie, David G Mutch · fiscal years 2023 to 2026Named on NCT07737795
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT01210222
- Gynecologic Oncology GroupU10CA027469 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI Philip J. DiSaia · fiscal years 1985 to 2013Named on NCT01210222, NCT00104910
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:53 UTC. The ranking covers the 200 most relevant of 349 PubMed records, and a shared surname and initials can bring in a namesake. All 349 on PubMed
- 2,326 citationsRCR 81.5
- 1,541 citationsRCR 71.0
- Zoledronic acid and clinical fractures and mortality after hip fracture.N Engl J Med · 20071,430 citationsRCR 43.4
- Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.J Clin Oncol · 20091,281 citationsRCR 31.5
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.J Clin Oncol · 20201,110 citationsRCR 51.8
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.N Engl J Med · 2019733 citationsRCR 27.1
- Effects of exercise training on older patients with major depression.Arch Intern Med · 1999673 citationsRCR 22.2
- Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months.Psychosom Med · 2000529 citationsRCR 16.4
- Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.J Clin Oncol · 2023441 citationsRCR 39.9
- 436 citationsRCR 41.6